Tags

Type your tag names separated by a space and hit enter

Comparison of the efficacy and safety of travoprost with a fixed-combination of dorzolamide and timolol in patients with open-angle glaucoma or ocular hypertension.
Curr Med Res Opin. 2006 Sep; 22(9):1799-805.CM

Abstract

PURPOSE

The purpose of this study was to compare travoprost (TRAV; travoprost 0.004%) and the fixed-combination of dorzolamide/timolol (DTFC; dorzolamide 2.0%/timolol maleate 0.5%) ophthalmic solutions for reducing intraocular pressure (IOP) in patients with primary open-angle glaucoma (OAG) or ocular hypertension (OHT).

METHODS

This was a randomized single masked, study with parallel controls. The TRAV group (n = 29) dosed once daily at 9:00 PM while the DTFC group (n = 27) dosed twice daily at 9:00 AM and 9:00 PM. IOP was measured at baseline, and following 3 weeks and 6 weeks of treatment at 8:00 AM, 12:00 PM, 4:00 PM, and 8:00 PM.

RESULTS

Mean average IOP reductions from baseline during the course of the day were 7.5 (32.7%) and 7.1 (30.7%) mmHg for TRAV and 4.8 (23.1%) and 4.5 (21.7%) mmHg for DTFC at 3 weeks and 6 weeks, respectively. The greater IOP reduction for patients receiving TRAV was statistically significant at both the 3 and 6 week visits when averaged across all four time points (p < 0.01). The two products were well-tolerated over the course of the 6 week study. Some factors such as taste perversion were reported more often in the DTFC group.

CONCLUSIONS

Travoprost monotherapy provided better efficacy in terms of IOP reduction and percentage of IOP reduction compared to dorzolamide 2.0%/timolol maleate 0.5% fixed combination.

Authors+Show Affiliations

Glaucoma Service of Santa Casa of Belo Horizonte-Minas Gerais, Brazil. drsuzuki@uol.com.brNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16968583

Citation

Suzuki, Emilio Rintaro, et al. "Comparison of the Efficacy and Safety of Travoprost With a Fixed-combination of Dorzolamide and Timolol in Patients With Open-angle Glaucoma or Ocular Hypertension." Current Medical Research and Opinion, vol. 22, no. 9, 2006, pp. 1799-805.
Suzuki ER, Franklin LM, da Silva LJ, et al. Comparison of the efficacy and safety of travoprost with a fixed-combination of dorzolamide and timolol in patients with open-angle glaucoma or ocular hypertension. Curr Med Res Opin. 2006;22(9):1799-805.
Suzuki, E. R., Franklin, L. M., da Silva, L. J., Figueiredo, C. R., Netto, J. A., & Batista, W. D. (2006). Comparison of the efficacy and safety of travoprost with a fixed-combination of dorzolamide and timolol in patients with open-angle glaucoma or ocular hypertension. Current Medical Research and Opinion, 22(9), 1799-805.
Suzuki ER, et al. Comparison of the Efficacy and Safety of Travoprost With a Fixed-combination of Dorzolamide and Timolol in Patients With Open-angle Glaucoma or Ocular Hypertension. Curr Med Res Opin. 2006;22(9):1799-805. PubMed PMID: 16968583.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of the efficacy and safety of travoprost with a fixed-combination of dorzolamide and timolol in patients with open-angle glaucoma or ocular hypertension. AU - Suzuki,Emilio Rintaro,Jr AU - Franklin,Luciana Meirelles, AU - da Silva,Luciano José Basilio, AU - Figueiredo,Carlos R L, AU - Netto,Joao Agostini, AU - Batista,Wagner Duarte, PY - 2006/9/14/pubmed PY - 2007/1/12/medline PY - 2006/9/14/entrez SP - 1799 EP - 805 JF - Current medical research and opinion JO - Curr Med Res Opin VL - 22 IS - 9 N2 - PURPOSE: The purpose of this study was to compare travoprost (TRAV; travoprost 0.004%) and the fixed-combination of dorzolamide/timolol (DTFC; dorzolamide 2.0%/timolol maleate 0.5%) ophthalmic solutions for reducing intraocular pressure (IOP) in patients with primary open-angle glaucoma (OAG) or ocular hypertension (OHT). METHODS: This was a randomized single masked, study with parallel controls. The TRAV group (n = 29) dosed once daily at 9:00 PM while the DTFC group (n = 27) dosed twice daily at 9:00 AM and 9:00 PM. IOP was measured at baseline, and following 3 weeks and 6 weeks of treatment at 8:00 AM, 12:00 PM, 4:00 PM, and 8:00 PM. RESULTS: Mean average IOP reductions from baseline during the course of the day were 7.5 (32.7%) and 7.1 (30.7%) mmHg for TRAV and 4.8 (23.1%) and 4.5 (21.7%) mmHg for DTFC at 3 weeks and 6 weeks, respectively. The greater IOP reduction for patients receiving TRAV was statistically significant at both the 3 and 6 week visits when averaged across all four time points (p < 0.01). The two products were well-tolerated over the course of the 6 week study. Some factors such as taste perversion were reported more often in the DTFC group. CONCLUSIONS: Travoprost monotherapy provided better efficacy in terms of IOP reduction and percentage of IOP reduction compared to dorzolamide 2.0%/timolol maleate 0.5% fixed combination. SN - 0300-7995 UR - https://www.unboundmedicine.com/medline/citation/16968583/Comparison_of_the_efficacy_and_safety_of_travoprost_with_a_fixed_combination_of_dorzolamide_and_timolol_in_patients_with_open_angle_glaucoma_or_ocular_hypertension_ DB - PRIME DP - Unbound Medicine ER -